343 related articles for article (PubMed ID: 15119982)
1. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of a randomized switch of patients from clozaril to generic clozapine.
Kluznik JC; Walbek NH; Farnsworth MG; Melstrom K
J Clin Psychiatry; 2001; 62 Suppl 5():14-7; discussion 23-4. PubMed ID: 11305843
[TBL] [Abstract][Full Text] [Related]
3. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
4. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
Argumosa A; Herranz JL
Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
7. Looking beyond the formulary budget in cost-benefit analysis.
Cohen LJ
Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
[TBL] [Abstract][Full Text] [Related]
8. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
[TBL] [Abstract][Full Text] [Related]
9. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
10. Clozapine for refractory schizophrenia: the Illinois experience.
Buckman RW; Malan RD
J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
[TBL] [Abstract][Full Text] [Related]
11. New vs. old antipsychotics: the Texas experience.
Reid WH
J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
[TBL] [Abstract][Full Text] [Related]
12. The generics in transplantation and the rules on their use.
Masri M
Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
[TBL] [Abstract][Full Text] [Related]
13. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
[TBL] [Abstract][Full Text] [Related]
14. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
16. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
Margolese HC; Wolf Y; Desmarais JE; Beauclair L
Int Clin Psychopharmacol; 2010 May; 25(3):180-2. PubMed ID: 20216221
[TBL] [Abstract][Full Text] [Related]
17. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
18. The pharmacoeconomics of clozapine: a review.
Meltzer HY; Cola PA
J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
[TBL] [Abstract][Full Text] [Related]
19. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
20. Generic clozapine: a cost-saving alternative to brand name clozapine?
Tse G; Thompson D; Procyshyn RM
Pharmacoeconomics; 2003; 21(1):1-11. PubMed ID: 12484800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
